Immunocheckpoint Inhibitor Therapy

PreclinicalSmall molecule

Immunocheckpoint Inhibitor Therapy is one of 45 small molecule programs targeting Intrahepatic Cholangiocarcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intrahepatic CholangiocarcinomaActive, not recruiting

Intrahepatic CholangiocarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

88 competitors in Intrahepatic Cholangiocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 2

11 2

Beyfortus

BeiGene

Phase 2

3 3

Fudr

Pfizer

Phase 2

2 4

Pemazyre

Incyte

Phase 2

2 5

Opdivo

Bristol-Myers Squibb

Phase 2

1 6

Keytruda

Merck & Co.

Phase 2

1 7

Rocaltrol

Alnylam Pharmaceuticals

Phase 2

1 8

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

9 9

Stivarga

Bayer

Phase 2

1 10

Anlotinib Hydrochloride

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intrahepatic Cholangiocarcinoma1 trial

TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma

Unknown status·TThe Central Hospital of Lishui City·N/A·NCT05247996·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immunocheckpoint Inhibitor Therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunocheckpoint Inhibitor Therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunocheckpoint Inhibitor Therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Central Hospital of Lishui City company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe Central Hospital of Lishui City

Immunocheckpoint Inhibitor Therapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intrahepatic Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News